small-molecule-inhibitors
(2)
Grace Science, LLC
Grace Science, LLC is a Palo Alto-based biotechnology company founded in 2017 by Silicon Valley entrepreneur Matt Wilsey and Nobel laureate chemist Dr. Carolyn Bertozzi to develop therapies built on the biology of NGLY1, an enzyme central to protein quality control. The company grew out of a father's search for a treatment after his daughter Grace was diagnosed with ultra-rare NGLY1 Deficiency. Its lead program, GS-100, is an AAV9 gene replacement therapy now in a Phase 1/2/3 clinical trial and holds FDA RMAT designation. Grace Science also pursues small-molecule and biomarker work that extends NGLY1 biology into oncology and neurodegeneration.
Josh Bilenker
Josh Bilenker is the CEO and co-founder of Treeline Biosciences, a Watertown, Massachusetts biotech building precision oncology medicines. A physician by training who once reviewed cancer drugs at the FDA, he founded Loxo Oncology in 2013 and took a tumor-agnostic, genomics-first approach he likened to 'moneyball' target selection. Loxo produced three FDA-approved medicines and was bought by Eli Lilly for roughly $8 billion in 2019. In 2021 he started Treeline with former Novartis research head Jeff Engelman, and in 2026 the company agreed to merge with Standard BioTools to go public as 'Treeline Biosciences' (Nasdaq: TRLN).